To address the role of STING activation and relationship with the tumor immune microenvironment, we utilized a previously described high risk, early stage breast tumor TMA where individuals were all treated surgically followed by adjuvant anthracycline-based chemotherapy.15,16 Following review for quality control, STING IHC was available for 156 tumors (clinicopathological characteristics in Supplementary Table 1). The gene discussed is STING1; the disease is breast neoplasm.